Skip to main content
Innovation

Enter our constantly evolving world

Enter our constantly evolving world

Innovation is part of of our DNA

Forward-thinking to the core, our passionate team is dedicated to researching and developing solutions to meet the current and future needs of the agri-food industry. It all began twenty years ago, with the growing popularity of seafood products, such as smoked salmon. As an increasing number of people enjoy seafood, the safety of these highly perishable products in refrigerated form is still a major challenge for the industry.

Our research focuses on improving the safety of these foods through reliable alternatives to chemical additives, which harm health. Knowing that many highly pathogenic bacteria, such as Listeria, Salmonella, E. coli and Clostridium botulinum, can survive in ready-to-eat products, we are constantly innovating to improve food safety.

Beyond smoked fish, we have the will and expertise to expand our horizons to other matrices, including meats, fruits and vegetables, in the near future. At Aliotech, we're determined to improve food safety today and tomorrow with our 100% Québec know-how.

A robust methodology

We isolated a Carnobacterium divergens strain from ready-to-eat seafood products, producing a new bacteriocin called divergicine M35 (Tahiri et al. 2004).

Molecular characterization of this peptide revealed a novel, thermostable, 43-amino-acid bacteriocin with a molecular weight of 4518 Da.

This process is economically viable and transferable to industry for producing the C. divergens-based ingredient and its bacteriocin.

We also aim to develop new ingredients based on divergicine M35 for different applications by Fumoir Grizzly.

About our collaboration with Dr. Ismail Fliss

Full Professor at the Département de sciences des aliments et de nutrition at Université Laval, Dr. Ismail Fliss is the driving force behind the development of the Carnobacterium divergens antimicrobial ingredient. In partnership with Fumoir Grizzly, he is also responsible for the process that led to the approval of this new food ingredient for the bioconservation of fresh seafood products.

A veterinarian by training, Dr. Fliss is recognized worldwide for his work on identifying, purifying, and using bacteriocins as natural antimicrobial agents in the food, medical and veterinary sectors. To date, he has published nearly 160 scientific articles and 10 book chapters. He holds 6 patents.

Always on the move, he continues his collaboration with Aliotech and Fumoir Grizzly to develop new ingredients based on divergicine M35 for other types of food and non-food applications.

Coming soon at Aliotech…

Innovation never stops at Aliotech! In collaboration with Dr. Ismail Fliss, we aim to develop an integrated large-scale fermentation and packaging process for producing C. divergens and/or divergicin-based ingredients. We also aim to develop a simple and efficient process for the large-scale purification of divergicine M35.

Research is also planned on the antimicrobial activity of divergicine M35. We will also completely characterize various divergicine M35-based ingredients to gain their approval as technological agents. At the same time, we will be carrying out a techno-economic analysis and an assessment of the production and utilization costs of divergicine M35-based ingredients.

Follow us in our quest for innovation

We look forward to sharing the fruit of our research with you!

Read our latest news
Follow us in our quest for innovation